STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

LB100

RMC-6291-101

STX-721-101

StrateGIST 1 (IDRX-42-001)

D6900C00001

CA1201001

M22TGA

CTLR-101

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

D9570C00001

GO43860

XL092-001

SGNPDL1V-001

INCB 123667-101

PROACTIVE

1479-0001

CyPep-1

VHIO17002

MCLA-128-CL01

KEYNOTE 158

DESTINY-Lung03

A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/​or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1].



<ul class="wp-block-list">
<li>Code NKI: M22DRX</li>



<li>Code firma: StrateGIST 1 (IDRX-42-001)</li>



<li>Code clinicaltrials.gov: NCT05489237</li>
</ul>



Principal Investigator



Dr. N. Steeghs



Drugs 



IDRX-42 (selective KIT inhibitor also inhibiting resistant mutations)



<h2 class="wp-block-heading">Summary</h2>



This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.



Read more on <a href="https://clinicaltrials.gov/study/NCT05489237?term=IDRX-42&amp;rank=1" data-type="URL" data-id="https://www.clinicaltrials.gov/study/NCT04868877?term=MCLA-129-CL01&amp;rank=1">clinicaltrials.gov</a>



<h3 class="wp-block-heading">Additional comments</h3>



The study is currently closed and it will open again.